Loading clinical trials...
Loading clinical trials...
Venetoclax (VEN) is a potent and selective oral inhibitor of the BCL-2 gene and has shown anti-leukemic activity when used in combination with hypomethylating agents (HMA) in patients with Acute Myelo...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
NCT06859424 · AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), and more
NCT07347171 · Leukemia, AML, and more
NCT06911710 · Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia), and more
NCT06899581 · AML (Acute Myelogenous Leukemia, HLH, and more
NCT06835140 · AML (Acute Myelogenous Leukemia), NK Cell, and more
Fondazione IRCCS Policlinico San Matteo, SC Oncologia
Pavia, Pavia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions